Real-world use and outcomes of belimumab in childhood-onset lupus: A single-center retrospective study

贝里穆马布 医学 单中心 回顾性队列研究 内科学 系统性红斑狼疮 儿科 中心(范畴论) 疾病 B细胞激活因子 免疫学 抗体 B细胞 化学 结晶学
作者
Jordan E. Roberts,Cordelia Burn,Rebecca E. Sadun,Emily A. Smitherman,Scott E. Wenderfer,Mary Beth F. Son
出处
期刊:Lupus [SAGE Publishing]
卷期号:32 (9): 1111-1116 被引量:10
标识
DOI:10.1177/09612033231187752
摘要

Studies of real-world effectiveness of belimumab in adults with systemic lupus erythematosus have shown improved disease control and decreased oral glucocorticoid use. However, belimumab use outside of clinical trial settings has not been well studied in childhood-onset systemic lupus erythematosus (cSLE). We aimed to characterize indications for belimumab use and evaluate oral glucocorticoid doses and disease activity scores in the year following belimumab initiation at a single, large pediatric rheumatology center.We included children and young adults with cSLE who received ≥ 1 dose of belimumab. Repeated measures one-way ANOVA was used to compare SLEDAI-2K scores and prednisone-equivalent daily oral glucocorticoid doses at baseline, 6 months, and 12 months after belimumab initiation for those who continued therapy for a year.We identified 21 patients with cSLE who received ≥ 1 dose of belimumab. The median disease duration at belimumab initiation was 30.8 months [IQR 21.0-79.1]. At the time of belimumab initiation, 100% of patients were taking an antimalarial, 81% were on oral glucocorticoids, and 91% were on at least one conventional DMARD. Thirteen patients (62%) continued belimumab for ≥6 months and 11 (52%) for ≥12 months. Among those continuing belimumab for ≥12 months, median [IQR] oral prednisone daily doses in milligrams at baseline, 6 months, and 12 months were 12.5 [7.5-17.5], 9 [6.25-10], and 5 [5-9.5], p = 0.037, and median [IQR] SLEDAI-2K scores at baseline, 6 months, and 12 months were 8 [5.5-10.5], 6 [3.5-10], and 6 [6-8.5], p = 0.548, respectively.In our cohort of pediatric patients with lupus and moderate disease activity treated with belimumab for ≥12 months, daily oral glucocorticoid doses were significantly lower 6 and 12 months after belimumab initiation than baseline. Use in patients with active nephritis was uncommon. Further research is needed in a large, multicenter cohort to determine the real-world effectiveness of belimumab in children and develop guidelines for use.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Crazykk完成签到,获得积分10
刚刚
1秒前
1秒前
Sunny完成签到,获得积分10
1秒前
研友_LX7Jq8完成签到,获得积分10
4秒前
何遇完成签到,获得积分10
4秒前
科研通AI5应助游游采纳,获得10
4秒前
小菜完成签到 ,获得积分10
5秒前
上官若男应助NorthWang采纳,获得10
6秒前
鲤鱼白玉发布了新的文献求助10
7秒前
zzz给zzz的求助进行了留言
7秒前
cocohan关注了科研通微信公众号
7秒前
敢超发布了新的文献求助10
7秒前
8秒前
9秒前
商凤琴发布了新的文献求助10
12秒前
feige完成签到 ,获得积分10
14秒前
隐形曼青应助敢超采纳,获得10
14秒前
动力小滋完成签到,获得积分10
14秒前
苏言发布了新的文献求助10
15秒前
emm发布了新的文献求助10
15秒前
张大泽同学完成签到 ,获得积分10
16秒前
17秒前
包容的怀绿完成签到,获得积分20
20秒前
23秒前
24秒前
喜悦芝麻完成签到 ,获得积分10
24秒前
25秒前
科研通AI5应助Evelyn采纳,获得10
26秒前
情怀应助kkkkkoi采纳,获得10
26秒前
好旺发布了新的文献求助10
30秒前
30秒前
30秒前
30秒前
32秒前
华仔应助王多多采纳,获得10
33秒前
33秒前
george发布了新的文献求助10
34秒前
包容的怀绿关注了科研通微信公众号
34秒前
cocohan发布了新的文献求助10
34秒前
高分求助中
IZELTABART TAPATANSINE 500
Where and how to use plate heat exchangers 400
Seven new species of the Palaearctic Lauxaniidae and Asteiidae (Diptera) 400
Handbook of Laboratory Animal Science 300
Fundamentals of Medical Device Regulations, Fifth Edition(e-book) 300
Beginners Guide To Clinical Medicine (Pb 2020): A Systematic Guide To Clinical Medicine, Two-Vol Set 250
A method for calculating the flow in a centrifugal impeller when entropy gradients are present 240
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3710387
求助须知:如何正确求助?哪些是违规求助? 3259414
关于积分的说明 9908521
捐赠科研通 2972539
什么是DOI,文献DOI怎么找? 1629886
邀请新用户注册赠送积分活动 773007
科研通“疑难数据库(出版商)”最低求助积分说明 744175